WEDNESDAY, June 7, 2023 (HealthDay News) For years, doctors have thought that a more extensive surgery that removes a wider swath of lymph nodes was the best option for
Matthew Galsky, MD, highlights updates in metastatic urothelial cancer treatment, as well as the evolution of PARP inhibitors and the optimal use of intensified triplet therapy in prostate cancer.
Extended follow-up from the CheckMate 274 trial further supports adjuvant nivolumab as a standard of care for patients with resected muscle-invasive urothelial carcinoma.